Table 3. Use of Cox proportional hazard model to analyze predictors for 3-year overall mortality in the 26 non-small cell lung cancer patients.
| Bivariate | Multivariate | |||
| Harzard Ratio | 95%ConfidenceInterval | Harzard Ratio | 95%ConfidenceInterval | |
| Age, years | 1.013 | 0.973–1.054 | ||
| Male sex | 0.854 | 0.279–2.612 | ||
| Tumor stage, IIIB versus IV | 0.973 | 0.382–2.477 | ||
| Squamous cell carcinoma versus adenocarcinoma | 0.48 | 0.189–1.221 | ||
| ECOG performance status | 2.581 | 0.825–8.075 | ||
| Smoking history of more than 10 pack-years | 6.402 | 1.502–27.296* | ||
| Percentage of S100A15 nuclear stained cell, % | 1.028 | 1.007–1.05* | 1.028 | 1.007-1.05* |
| Nuclear S100A15 percentage positivity score | 1.701 | 1.094–2.645* | ||
| Nuclear S100A15 staining intensity score | 1.547 | 1.013–2.363* | ||
| Nuclear S100A15 total score | 1.354 | 1.053–1.741* | ||
| Percentage of S100A15 cytoplasmic stained cell, % | 0.986 | 0.96–1.011 | ||
| Cytoplasmic S100A15 percentage positivity score | 0.822 | 0.533–1.266 | ||
| Cytoplasmic S100A15 staining intensity score | 0.31 | 0.099–0.975* | ||
| Cytoplasmic S100A15 total score | 0.779 | 0.541–1.12 | ||
| Diabetes mellitus | 0.938 | 0.214–4.102 | ||
| Hypertension | 1.151 | 0.443–2.99 | ||
| Chronic obstructive pulmonary disease | 3.581 | 1.247–10–298* | ||
| Chronic hepatitis | 1.052 | 0.24–4.614 | ||
| Chronic kidney disease | 0.042 | 0–118.7 | ||
| Congestive heart failure | 1.807 | 0.232–14.053 | ||
*
p<0.05.